$5.42 -0.4 -6.7%
Last Trade - 9:00pm
| Market Cap | ÂŁ177.6m |
| Enterprise Value | ÂŁ146.7m |
| Revenue | ÂŁn/a |
| Position in Universe | 4231st / 6643 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.35 | 47.4 | 39.5 | 24.2 | 41.7 | 2.45 | 0.33 | +0.8% | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
| Last Annual | June 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | October 24, 2003 |
| Public Since | March 27, 2014 |
| No. of Shareholders: | 30 |
| No. of Employees: | 83 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Market |
| Shares in Issue | 42,657,878 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 14193 Nw 119Th Terrace Suite #10, ALACHUA, 32615, United States |
| Web | https://www.agtc.com/ |
| Phone | +1 386 4622204 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 9:00pm, shares in Applied Genetic Technologies are trading at $5.42, giving the company a market capitalisation of ÂŁ177.6m. This share price information is delayed by 15 minutes.
Shares in Applied Genetic Technologies are currently trading at $5.42 and the price has moved by 20.54% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Applied Genetic Technologies price has moved by -7.22% over the past year.
Of the analysts with advisory recommendations for Applied Genetic Technologies, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Applied Genetic Technologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Applied Genetic Technologies is scheduled to issue upcoming financial results on the following dates:
Applied Genetic Technologies does not currently pay a dividend.
Applied Genetic Technologies does not currently pay a dividend.
Applied Genetic Technologies does not currently pay a dividend.
To buy shares in Applied Genetic Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Applied Genetic Technologies are currently trading at $5.42, giving the company a market capitalisation of ÂŁ177.6m.
Here are the trading details for Applied Genetic Technologies:
Based on an overall assessment of its quality, value and momentum, Applied Genetic Technologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Applied Genetic Technologies are currently priced at $5.42. At that level they are trading at 0.204% discount to the analyst consensus target price of 0.00.
Analysts covering Applied Genetic Technologies currently have a consensus Earnings Per Share (EPS) forecast of -2.002 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Applied Genetic Technologies. Over the past six months, the relative strength of its shares against the market has been -12.32%. At the current price of $5.42, shares in Applied Genetic Technologies are trading at 12% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Applied Genetic Technologies.
Applied Genetic Technologies's management team is headed by:
Here are the top five shareholders of Applied Genetic Technologies based on the size of their shareholding:
